Kara Johnson

Functional genomic landscape of acute myeloid leukaemia

Jeffrey Tyner, Cristina E. Tognon, Daniel Bottomly et al. · Nature · 2018 · 1.4K citations · Full text

Hematological Malignancy, Chromatin, Functional Genomics +7

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Heather A. Bradeen, Christopher A. Eide, Thomas O’Hare et al. · Blood · 2006 · 397 citations · Full text

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Daniel Bottomly, Nicola Long, Anna Reister Schultz et al. · Cancer Cell · 2022 · 336 citations · Full text

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Ian J. Griswold, Mary MacPartlin, Thomas G.P. Bumm et al. · Molecular and Cellular Biology · 2006 · 198 citations · Full text

Imatinib Resistance, Signal Transduction, Imatinib Binding +13

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl–positive cell lines

Paul La Rosée, Kara Johnson, Amie S. Corbin et al. · Blood · 2003 · 103 citations · Full text